Harte Group Expands Global Network to Support Pharmaceutical Companies
Doylestown, Pa.
Harte Group, a global company who manages and represents Functional Service Providers for support of clinical development needs, announced that its growing network of partners has reached 44 companies, employing over 7,900 experienced staff with an average company life of 13 years in business.
Due to a changing landscape within clinical development operations and the market being underserved by the existing full-service CRO model, the Harte Group created a full-service CRO offering - one built by leveraging smaller companies. Many sponsors have been looking for alternatives to support smaller programs in their portfolio, as well as looking for more ways to execute their clinical programs and projects.
"I am excited by the high level of interest in this Functional Services Provider model," said Michael Harte, Founder & President of the Harte Group. Harte mentioned that their team is in active discussions with both large pharma and smaller biotechnology firms.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
